Tuesday, 30 July 2024
by BD Banks
Shares of Integra Lifesciences (NASDAQ: IART) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened.
Integra reported Q2 revenue of $418.2 million, up 9.7% year over year. This topped the average analyst revenue estimate of nearly $413.2 million.
The company posted a loss per share of $0.16, based on generally accepted accounting principles (GAAP). Integra announced adjusted earnings per share (EPS) of $0.63. Although this reflected a decline from adjusted EPS of $0.71 in the prior-year period, it narrowly beat the consensus estimate of $0.62.
Integra’s Q2 numbers weren’t the reason for the sell-off, though, as the company’s updated full-year guidance disappointed investors. It now projects that full-year revenue will be between $1.609 billion and $1.629 billion, with adjusted EPS of $2.41 to $2.57. Both ranges are well below Wall Street’s consensus full-year estimates.
In May, Integra’s full-year outlook was for revenue between $1.672 billion and $1.687 billion, with adjusted EPS of $3.01 to $3.11. Why did the company lower its guidance in its Q2 update? CEO Jan De Witte said that the reduction “reflects an updated view of our operational challenges and critical investments in our compliance improvement program that will allow our supply to meet our strong commercial demand strength over time.”
Integra Lifesciences could bounce back. However, I don’t think the stock is a buy right now. Other stocks provide much more attractive risk-reward propositions.
Before you buy stock in Integra LifeSciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Integra LifeSciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $692,784!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of July 29, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.